In a nutshell, the federal independent dispute resolution IDR process is the process in which arbitrators decide certain disputes between providers and payors that qualify as surprise billing situations under No Surprises Act
VIAC Releases Vienna Investment Arbitration Rules | Dechert LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Clean energy future requires electricity, gas, and infrastructure
Posted : 2021-03-13 09:39 By Kang Joo-myung
International Gas Union (IGU) President Kang Joo-myung / Courtesy of IGUThe global debate about climate change and the role of energy is at a critical juncture. That debate in recent years has been intense and loud, but we have not come far in aligning on an approach that enables us to meet the enormous challenges of decarbonization, energy access and energy security.
In the coming months, we have a real opportunity to do so ― with President Joe Biden s Climate Summit, the G20 meeting under an Italian presidency and COP26 under the leadership of the U.K. It will require a clarity of purpose and approach that has been lacking to date. This is not the time for politics and self-interest. We have to settle on an approach that delivers clean, secure and affordable energy.
To embed, copy and paste the code into your website or blog:
On December 27, 2020, Congress signed the Consolidated Appropriations Act, 2021, into law. The omnibus act includes new legislation affecting patent, copyright and trademark law. A brief summary of key provisions is provided below.
Patents – Section 325 Biological Product Patent Transparency
42 USC § 262(k) was amended to require that the US Food and Drug Administration (FDA) provide the public with more information about patented biological products. Within six months, the FDA must make the following information available to the public on its Database of Licensed Biological Products or “Purple Book,” and it must update the list every 30 days:
IP Implications of the Consolidated Appropriations Act, 2021 Thursday, January 14, 2021
On December 27, 2020, Congress signed the Consolidated Appropriations Act, 2021, into law. The omnibus act includes new legislation affecting patent, copyright and trademark law. A brief summary of key provisions is provided below.
Patents – Section 325 Biological Product Patent Transparency
42 USC § 262(k) was amended to require that the US Food and Drug Administration (FDA) provide the public with more information about patented biological products. Within six months, the FDA must make the following information available to the public on its Database of Licensed Biological Products or “Purple Book,” and it must update the list every 30 days: